Were Analysts Bearish INSYS Therapeutics, Inc. (NASDAQ:INSY) This Week?

April 17, 2018 - By Linda Rogers

Investors sentiment decreased to 0.76 in Q4 2017. Its down 0.49, from 1.25 in 2017Q3. It worsened, as 21 investors sold INSYS Therapeutics, Inc. shares while 29 reduced holdings. 20 funds opened positions while 18 raised stakes. 16.43 million shares or 9.75% less from 18.21 million shares in 2017Q3 were reported.
Bancshares Of Montreal Can owns 70,116 shares. The Korea-based Mirae Asset Global Investments Ltd has invested 0.19% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Alliancebernstein Limited Partnership holds 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 74,620 shares. Panagora Asset Mgmt Inc has invested 0.01% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Pnc Ser Group Inc Inc stated it has 100 shares. Deutsche Fincl Bank Ag reported 53,827 shares. Qs Invsts Ltd Limited Liability Company invested in 0.02% or 171,071 shares. Brown Brothers Harriman & accumulated 3,765 shares. Susquehanna Group Ltd Liability Partnership holds 119,608 shares. National Bank Of Mellon Corp reported 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Legal And General Group Inc Pcl reported 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Fmr Limited Com holds 173,684 shares. Gam Hldgs Ag holds 0.02% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 83,940 shares. Vanguard Gp Inc has invested 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Meeder Asset Mgmt holds 0% or 355 shares in its portfolio.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Ratings Coverage

Among 3 analysts covering Insys Therapeutics (NASDAQ:INSY), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Insys Therapeutics had 4 analyst reports since October 18, 2017 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Wednesday, October 18. RBC Capital Markets maintained the shares of INSY in report on Friday, October 27 with “Buy” rating. PiperJaffray downgraded the stock to “Underweight” rating in Friday, March 9 report. Jefferies maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) rating on Friday, November 3. Jefferies has “Buy” rating and $11 target. Below is a list of INSYS Therapeutics, Inc. (NASDAQ:INSY) latest ratings and price target changes.

09/03/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Underweight Downgrade
03/11/2017 Broker: Jefferies Rating: Buy Old Target: $14 New Target: $11 Maintain
27/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $8.0 Maintain
18/10/2017 Broker: Jefferies Rating: Buy New Target: $14.0 Maintain

The stock increased 9.30% or $0.5832 during the last trading session, reaching $6.8532. About 589,048 shares traded. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 45.03% since April 17, 2017 and is downtrending. It has underperformed by 56.58% the S&P500.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $505.52 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.